TY - JOUR
T1 - Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
AU - Parra, Claudia
AU - González, John Mario
AU - Castañeda, Elizabeth
AU - Fiorentino, Susana
PY - 2005/3
Y1 - 2005/3
N2 - BACKGROUND: Cryptococcus neoformans is a widely disseminated fungus shown to be responsible for infections in individuals with impaired cell mediated immunity, such as patients with human immunodeficiency virus (HIV). Cryptococcus neoformans has a polysaccharide capsule composed of glucuronoxylomannan (GXM), which acts as a major virulence factor and is considered to be a thymus independent type-2 antigen (TI-2). OBJECTIVE: In the current study, the production kinetics were evaluated for IgG subclasses specific for GXM, and assessed with the cross reactive antibodies to Streptococcus pneumoniae polysaccharide. In addition, spleen B cell subpopulations were quantified in murine models of cryptococcosis with different susceptibilities to the infection. MATERIALS AND METHODS: Antibodies were detected by ELISA at different time intervals after C. neoformans infection in moderately resistant (Balb/c), highly resistant (CBA/j) and susceptible (C57BL/6) mouse strains. B cells subpopulations were determined by flow cytometry analysis. RESULTS: Early production of IgG1, described as protector antibodies, coincided with a decrease of the number of C. neoformans colony forming units in the lungs. Polysaccharide cross-reactive antibodies were detected in each of the three mouse strains. Antibody titers were highest in the susceptible strain (C57BL/6), a strain which also showed the highest proportion of splenic CD5+ B lymphocytes. In contrast, CBA/J mice showed the highest levels of CD43+ B. CONCLUSIONS: These findings suggest that IgG1 antibodies specific for GXM, are implicated in host protection against C. neoformans infection and may be regulated by CD43+ cells. They also suggest that cross reactivity antibodies are not important in the protection against C. neoformans infection.
AB - BACKGROUND: Cryptococcus neoformans is a widely disseminated fungus shown to be responsible for infections in individuals with impaired cell mediated immunity, such as patients with human immunodeficiency virus (HIV). Cryptococcus neoformans has a polysaccharide capsule composed of glucuronoxylomannan (GXM), which acts as a major virulence factor and is considered to be a thymus independent type-2 antigen (TI-2). OBJECTIVE: In the current study, the production kinetics were evaluated for IgG subclasses specific for GXM, and assessed with the cross reactive antibodies to Streptococcus pneumoniae polysaccharide. In addition, spleen B cell subpopulations were quantified in murine models of cryptococcosis with different susceptibilities to the infection. MATERIALS AND METHODS: Antibodies were detected by ELISA at different time intervals after C. neoformans infection in moderately resistant (Balb/c), highly resistant (CBA/j) and susceptible (C57BL/6) mouse strains. B cells subpopulations were determined by flow cytometry analysis. RESULTS: Early production of IgG1, described as protector antibodies, coincided with a decrease of the number of C. neoformans colony forming units in the lungs. Polysaccharide cross-reactive antibodies were detected in each of the three mouse strains. Antibody titers were highest in the susceptible strain (C57BL/6), a strain which also showed the highest proportion of splenic CD5+ B lymphocytes. In contrast, CBA/J mice showed the highest levels of CD43+ B. CONCLUSIONS: These findings suggest that IgG1 antibodies specific for GXM, are implicated in host protection against C. neoformans infection and may be regulated by CD43+ cells. They also suggest that cross reactivity antibodies are not important in the protection against C. neoformans infection.
UR - http://www.scopus.com/inward/record.url?scp=22344431905&partnerID=8YFLogxK
U2 - 10.7705/biomedica.v25i1.1332
DO - 10.7705/biomedica.v25i1.1332
M3 - Article
C2 - 15962907
AN - SCOPUS:22344431905
SN - 0120-4157
VL - 25
SP - 110
EP - 119
JO - Biomedica
JF - Biomedica
IS - 1
ER -